Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Research

• Publication date

  2015-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-14-1931PMID 25681274PMCID PMC4458508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody Drug Conjugates for Cancer Therapy

  2016cited by this paper
• Ieee Transactions On Cybernetics

  2015cited by this paper
• An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.

  2014cited by this paper
• Dual Targeting of Integrin αvβ3 and Matrix Metalloproteinase-2 for Optical Imaging of Tumors and Chemotherapeutic Delivery

  2014cited by this paper
• New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology

  2013cited by this paper
• Lessons Learned from Radiation Oncology Clinical Trials

  2013cited by this paper
• Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.

  2013cited by this paper
• Efficacy and safety of dendrimer nanoparticles with coexpression of tumor necrosis factor-α and herpes simplex virus thymidine kinase in gene radiotherapy of the human uveal melanoma OCM-1 cell line

  2013cited by this paper
• Selective Targeting of Brain Tumors with Gold Nanoparticle-Induced Radiosensitization

  2013cited by this paper
• Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides.

  2013cited by this paper
• Fluorescence-guided surgery with live molecular navigation — a new cutting edge

  2013cited by this paper
• Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer.

  2013cited by this paper
• Strategies for optimizing the response of cancer and normal tissues to radiation

  2013cited by this paper
• Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

  2013cited by this paper
• Advanced-stage pancreatic cancer: therapy options

  2013cited by this paper
• Maturing antibody–drug conjugate pipeline hits 30

  2013cited by this paper
• Maturing antibody–drug conjugate pipeline hits 30

  2013cited by this paper
• opportunities and Challenges in the era of molecularly targeted agents and radiation therapy

  2013cited by this paper
• Nanomedicine in chemoradiation.

  2013cited by this paper
• Antibody-drug conjugates in cancer therapy.

  2013cited by this paper
• Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.

  2013cited by this paper
• Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts

  2012cited by this paper
• RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating αvβ3 expression

  2012cited by this paper
• Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain.

  2012cited by this paper
• Ionizing radiation increases systemic nanoparticle tumor accumulation.

  2012cited by this paper
• X‐ray irradiation and Rho‐kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa‐2, which exhibits mesenchymal and amoeboid motility

  2011cited by this paper
• Targeting ανβ3 and ανβ5 inhibits photon-induced hypermigration of malignant glioma cells

  2011cited by this paper
• Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1

  2011cited by this paper
• The current landscape of locally advanced rectal cancer

  2011cited by this paper
• Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.

  2010cited by this paper
• The role of radiotherapy in locally advanced pancreatic carcinoma

  2010cited by this paper
• Parallel in Vivo and in Vitro Selection Using Phage Display Identifies Protease-dependent Tumor-targeting Peptides*

  2010cited by this paper
• Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer

  2010cited by this paper
• In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer.

  2009cited by this paper
• Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides.

  2009cited by this paper
• Up‐regulation of integrin β3 in radioresistant pancreatic cancer impairs adenovirus‐mediated gene therapy

  2009cited by this paper
• Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen

  2006cited by this paper
• Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.

  2005cited by this paper
• Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion.

  2005cited by this paper
• Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.

  2005cited by this paper
• Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy

  2005cited by this paper
• Tumor imaging by means of proteolytic activation of cell-penetrating peptides.

  2004cited by this paper
• Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels.

  2003cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells

  2001cited by this paper
• MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells.

  2001cited by this paper
• Radiation-Mediated Control of Drug Delivery

  2001cited by this paper
• Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.

  2000influential reference
• Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer

  2000cited by this paper
• Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft.

  1996influential reference
• Spatial and temporal control of gene therapy using ionizing radiation

  1995cited by this paper
• Taxol: a novel radiation sensitizer.

  1992cited by this paper
• Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.

  1990cited by this paper
• Variations in several responses of HeLa cells to x-irradiation during the division cycle.

  1963cited by this paper

• Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responses

  2026cites this paper
• Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy.

  2026cites this paper
• Aptamer-based drug delivery for targeted therapy of imatinib-resistant gastrointestinal stromal tumor

  2025cites this paper
• A dual-targeting peptide–drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer

  2025cites this paper
• Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics.

  2025cites this paper
• MMAE-Based Peptide-Drug Conjugates Targeting GPC3 for Precision Chemoradiotherapy in Hepatocellular Carcinoma.

  2025cites this paper
• Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy.

  2025cites this paper
• Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.

  2025cites this paper
• A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumors

  2025cites this paper
• Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies

  2025cites this paper
• 177Lu-labeled antibody-drug conjugate: a dual mechanistic treatment modality in solid tumors.

  2025cites this paper
• Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs

  2025cites this paper
• Antibody-Drug Conjugates in breast cancer.

  2025cites this paper
• Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy.

  2025cites this paper
• The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

  2024cites this paper
• Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment

  2024cites this paper
• Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions

  2024cites this paper
• Unmet needs in cervical cancer – can biological therapies plug the gap?

  2024cites this paper
• Mogamulizumab and Concomitant Hypofractionated Low-Dose Total Skin Electron Beam Therapy (2 × 4 Gy) in Cutaneous T-Cell Lymphoma: Proof of Principle, Report of Two Cases

  2024cites this paper
• Design and synthesis of novel site-specific antibody-drug conjugates that target TROP2.

  2024cites this paper
• Promising immunotherapeutic approaches for primary effusion lymphoma

  2024cites this paper
• Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy

  2024cites this paper
• Ras-Targeting Stabilized Peptide Increases Radiation Sensitivity of Cancer Cells.

  2024cites this paper
• Small Molecule‐Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs

  2024cites this paper
• Sustained and Localized Drug Depot Release Using Radiation‐Activated Scintillating Nanoparticles

  2024cites this paper
• Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel Antibody-Drug Conjugates.

  2024cites this paper
• Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers

  2024cites this paper
• Click Chemistry Selectively Activates an Auristatin Protodrug with either Intratumoral or Systemic Tumor-Targeting Agents

  2023cites this paper
• Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases

  2023cites this paper
• Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment

  2023cites this paper
• Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy

  2023influential citation
• Blue marine therapy: sea as a trove of natural anticancer drugs.

  2023cites this paper
• An antibody-drug conjugate directed to tissue factor shows preclinical anti-tumor activity in head and neck cancer as a single agent and in combination with chemoradiotherapy.

  2023cites this paper
• Development of peptides for targeting cell ablation agents concurrently to the Sertoli and Leydig cell populations of the testes: An approach to non-surgical sterilization

  2023cites this paper
• Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions

  2023cites this paper
• Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

  2023cites this paper
• An Overview of the EORTC-CLTG 2022 Congress

  2022cites this paper
• Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery

  2022cites this paper
• Targeted Chemoradiotherapy of Prostate Cancer Using Gold Nanoclusters with Protease Activatable Monomethyl Auristatin E.

  2022cites this paper
• Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

  2022cites this paper
• An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer.

  2022cites this paper
• Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy

  2022cites this paper
• Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy

  2022cites this paper
• A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models

  2022cites this paper
• Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology

  2022cites this paper
• Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.

  2022cites this paper
• Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs

  2021cites this paper
• Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade

  2021cites this paper
• Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen

  2021cites this paper
• Targeted nanomedicine modalities for prostate cancer treatment.

  2021cites this paper
• Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody

  2020cites this paper
• Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.

  2020cites this paper
• New Cell-Penetrating Peptide (KRP) with Multiple Physicochemical Properties Endows Doxorubicin with Tumor Targeting and Improves Its Therapeutic Index.

  2019cites this paper
• Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer.

  2019cites this paper
• Tumor-microenvironment controlled nanomicelles with AIE property for boosting cancer therapy and apoptosis monitoring.

  2019cites this paper
• Development of a new class of ligand-targeted chemotherapeutics with enhanced safety and efficacy profile

  2019cites this paper
• Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability

  2019cites this paper
• Therapeutic Potential of CPPs

  2019cites this paper
• Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents

  2019cites this paper
• An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer

  2019cites this paper
• Targeting Peptide‐Based Probes for Molecular Imaging and Diagnosis

  2018cites this paper
• Nanoparticle Augmented Radiotherapy using Titanium Oxide Nanoparticles

  2018cites this paper
• Impact of MMP-2 and MMP-9 enzyme activity on wound healing, tumor growth and RACPP cleavage

  2018cites this paper
• Roger Yonchien Tsien. 1 February 1952—24 August 2016

  2018cites this paper
• Cancer Radiosensitizers.

  2018cites this paper
• 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

  2018cites this paper
• Impact of MMP-2 and MMP-9 activation on wound healing, tumor growth and RACPP cleavage

  2018cites this paper
• Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers

  2017cites this paper
• Quercetin suppresses Dna double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway

  2017cites this paper
• Quercetin suppresses Dna double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway

  2017cites this paper
• Quercetin suppresses Dna double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway

  2017cites this paper
• Developments and future clinical outlook of taxane nanomedicines.

  2017cites this paper
• O-GlcNAcylation of fumarase maintains tumour growth under glucose deficiency

  2017cites this paper
• Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway

  2017cites this paper
• Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

  2017cites this paper
• RGD-Binding Integrins in Head and Neck Cancers

  2017cites this paper
• Marine Mollusk‐Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance

  2016cites this paper
• Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

  2016cites this paper
• Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth

  2016cites this paper
• Antibody drug conjugates: the future of chemotherapy?

  2016cites this paper
• Advances in fluorescent-image guided surgery.

  2016cites this paper
• Advancement in integrin facilitated drug delivery.

  2016cites this paper